Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing with Global Health Support

JUPITER, Fla., August 31st, 2026, FinanceWire

Support from the Gates Foundation, CEPI and the European Vaccines Hub highlights Dyadic’s potential to accelerate vaccine, antibody and biologics development while improving manufacturing productivity, scalability and affordability

Dyadic International, Inc. (Nasdaq: DYAI), a biotechnology company focused on developing scalable, cost-efficient protein production technologies, is advancing efforts to transform how vaccines, monoclonal antibodies, therapeutic proteins, and other biologic products are developed and manufactured.

Through grant funding and other forms of support from organizations including the Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), and the European Vaccines Hub for Pandemic Readiness (EVH), Dyadic is working to demonstrate how its proprietary C1 gene-expression platform may help overcome longstanding limitations in traditional biologics manufacturing.

The goal is significant: enable essential medicines and other biological products to be developed faster, manufactured more efficiently and supplied at lower cost—potentially expanding access to critical products around the world.

CEPI is a global partnership dedicated to accelerating the development of vaccines and other biologic countermeasures against epidemic and pandemic threats. EVH is a €170 million European consortium established to strengthen European Union pandemic preparedness through an integrated network supporting the research and development of safe and effective vaccines and monoclonal antibodies.

Their support reflects a broader challenge facing biotechnology: scientific discovery is accelerating rapidly, but the ability to manufacture those discoveries efficiently at commercial scale remains a critical bottleneck.

Unlocking the Power of AI Through Biotechnology

Artificial intelligence is rapidly changing how scientists discover and design proteins, antibodies, enzymes and other biomolecules. AI systems can increasingly generate promising molecular structures and DNA sequences at unprecedented speed.

But designing a molecule digitally is only the beginning.

Those DNA sequences must still be converted into real, functional products that can be manufactured reliably, rapidly and economically at scale.

Dyadic believes its C1 and Dapibus protein-production platforms can serve as part of that biological manufacturing engine—helping convert AI-enabled DNA designs into tangible products ranging from vaccines and life-saving medicines to nutritional proteins, food and beverage ingredients, renewable-fuel enzymes and other sustainable biological products.

In this emerging biotechnology landscape, AI may help determine what to build, while advanced expression platforms such as Dyadic’s may help determine how efficiently it can actually be made.

Closing the Gap Between Discovery and Manufacturing

Dyadic’s C1 platform is designed to help reduce the critical period between identifying a biological need and manufacturing an effective product.

Traditional biologics-production systems can be complex, expensive and time-consuming to develop and scale. During an epidemic or pandemic, those limitations can have serious consequences, particularly in low- and middle-income countries and regions where advanced manufacturing infrastructure is limited.

Using engineered fungal production systems, Dyadic is working to accelerate the development and production of vaccine antigens, monoclonal antibodies, therapeutic proteins, enzymes and other recombinant products.

The company’s platforms are designed to combine several important manufacturing characteristics, including rapid stable-cell-line development, short fermentation cycles, high levels of secreted protein production, economical chemically defined media and scalability using conventional microbial fermentation infrastructure.

Together, these capabilities could enable certain proteins to be manufactured more rapidly, in greater quantities and at lower cost than may be possible using some traditional production systems.

Just as importantly, the technology could potentially broaden the range of facilities and geographic regions capable of manufacturing sophisticated biological products.

A Potential New Model for Global Health Preparedness

The implications extend far beyond manufacturing efficiency.

When vaccines and treatments can be developed rapidly, manufactured economically and produced closer to where they are needed, countries may be better positioned to respond to emerging outbreaks before they become larger international crises.

Lower-cost and more flexible manufacturing could also improve access to biologic medicines used for endemic infectious diseases and other serious health conditions.

Recent pandemics demonstrated that scientific discovery alone is not sufficient. The world also requires manufacturing platforms capable of translating scientific breakthroughs into products at sufficient scale, consistent quality and economically sustainable cost.

A vaccine, antibody, nutritional protein or industrial enzyme can only create meaningful impact if it can ultimately be manufactured and delivered.

That makes innovation in manufacturing potentially just as important as innovation in discovery.

From Global Health to the Bioeconomy

Dyadic’s technology also carries potential applications beyond vaccines and therapeutics.

The same underlying ability to efficiently manufacture proteins can potentially support improved nutrition, alternative proteins, industrial enzymes, renewable fuels and other components of the growing global bioeconomy.

As AI dramatically expands the number of proteins and biological molecules that can be designed, scalable production technologies will become increasingly important.

Dyadic is positioning its C1 and Dapibus platforms at this intersection of artificial intelligence, biotechnology and advanced manufacturing.

By helping shorten development timelines, improve production yields, expand manufacturing flexibility and reduce costs, Dyadic’s technologies could emerge as important tools across pandemic preparedness, routine healthcare, nutrition and sustainability.

The company’s work with leading global-health organizations underscores the growing recognition that the next major breakthrough in biotechnology may not come solely from discovering a new molecule—but from developing a better way to manufacture it.

For Dyadic International, Inc. (Nasdaq: DYAI), the opportunity is to unlock the power of AI by turning DNA into useful products through scalable, economical biotechnology.

If successful, that capability could help protect human health, improve access to nutrition, advance sustainable manufacturing and strengthen global preparedness—while helping ensure that lifesaving scientific innovation can reach the people who need it most.

About Dyadic International, Inc.

Dyadic International, Inc. (Nasdaq: DYAI) is a biotechnology company focused on developing and applying its proprietary microbial protein-production platforms, including C1 and Dapibus, to support the development and manufacture of biologic vaccines, therapeutics, nutritional products and industrial applications. The company seeks to enable faster, more scalable and cost-efficient production of recombinant proteins for global health and commercial markets.

Contact